Application Area | Gene Edit (CRISPR Action) | Purpose | Therapeutic Benefit

I. Allogeneic (Off-the-Shelf) Product | T-Cell Receptor (TCR) Knockout (via TRAC locus) | Prevents Graft-versus-Host Disease (GvHD), where donor T-cells attack the patient's healthy tissues. | Enables a universal donor product that is safe for any patient.

I. Allogeneic (Off-the-Shelf) Product | MHC Class I (B2M gene) Knockout | Prevents Host Rejection, where the patient's own immune system would recognize and destroy the foreign donor T-cells. | Allows the allogeneic CAR-T cells to persist and remain active in the patient.

II. Potency and Persistence | PD-1 Knockout (Programmed Death-1) | Removes an immune checkpoint inhibitor that cancer cells use to "switch off" T-cells. | Prevents T-cell exhaustion and prolongs their anti-tumor activity.

II. Potency and Persistence | TGFBR2 Knockout (TGF-β Receptor) | Blocks the signal from TGF-β, a powerful immunosuppressive cytokine abundant in solid tumors. | Enables CAR-T cells to resist the suppressive tumor environment, improving solid tumor efficacy.

II. Potency and Persistence | Precise CAR Knock-in | Inserting the CAR gene into a specific, active genomic site (like the TRAC locus) rather than randomly. | Ensures stable, uniform, and optimal expression of the CAR, leading to better function and longevity.